![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Both European Group for blood and marrow transplantation risk score (EBMT score modified model) and hematopoietic cell transplantation comorbidity index (HCT-CI) are suitable for evaluating patients undergoing unmanipulated haploidentical blood and marrow transplantation (HBMT), while the predictive capacity of the combined model following haploidentical transplantation is still unknown. In this study, we calculated and validated 322 consecutive unmanipulated HBMT patients. Patients in groups with HCT-CI scores of 0 or 1–2 exhibited similar overall survival (OS), non-relapse mortality (NRM), and relapse rates, independent of their EBMT score modified model. In the group in which patients’ HCT-CI scores were ≥3, patients with high EBMT score modified model showed lower OS (p = 0.003) and higher NRM (p = 0.001) than did patients with low EBMT score. In conclusion, this combined model can be used to predict outcomes and may improve the stratification of high-risk patients following unmanipulated HBMT.
Acknowledgements
We thank Lisa M, medical editors at American Journal Experts, for providing editing assistance to the authors during the preparation of this manuscript.
Potential conflict of interest
This work was supported (in part) by the National High Technology Research and Development Program of China [Program 863; Grant No. 2013AA020401], the Key Program of the National Natural Science Foundation of China [Grant No. 81230013], the Scientific Research Foundation for Capital Medicine Development [Grant No. 2011-4022-08], and the National Natural Science Foundation of China [Grant No. 30971292]. Disclosure forms provided by the authors are available with the full text of this article at http://10.3109/10428194.2015.1124990